Acasti Pharma Inc ACST:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 10/19/21 EDT
1.75quote price arrow up+0.02 (+1.16%)
Volume
13,137
Close
1.73UNCH (UNCH)
Volume
216,726
52 week range
1.37 - 9.76
Loading...
  • Open1.73
  • Day High1.74
  • Day Low1.68
  • Prev Close1.71
  • 52 Week High9.76
  • 52 Week High Date02/10/21
  • 52 Week Low1.37
  • 52 Week Low Date11/06/20

Key Stats

  • Market Cap45.27M
  • Shares Out26.05M
  • 10 Day Average Volume0.39M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-33.46

KEY STATS

  • Open1.73
  • Day High1.74
  • Day Low1.68
  • Prev Close1.71
  • 52 Week High9.76
  • 52 Week High Date02/10/21
  • 52 Week Low1.37
  • 52 Week Low Date11/06/20
  • Market Cap45.27M
  • Shares Out26.05M
  • 10 Day Average Volume0.39M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-33.46

RATIOS/PROFITABILITY

  • EPS (TTM)-1.11
  • P/E (TTM)-1.56
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Acasti Pharma Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Acasti Pharma Inc. is a late-stage specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: Subarachnoid Hemorrhage (SAH), Ataxia Telangiectasia (A-T), and Postherpetic Neuralgia (PHN). The Company's lead product candidate includes GTX-104, which is a clinical-stage nanoparticle formulation of nimodipine being developed for IV infusion in SAH patients. The Company's...
Roderick Carter
Chairman
Janelle D'Alvise
President
Pierre Lemieux Ph.D.
Chief Operating Officer
Brian Ford CPA
Chief Financial Officer
Address
102-3009 boul. de la Concorde E
Laval, QC
H7E 2B5
Canada